Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT12396

Small molecule · Inhibitor of Janus-associated kinase 2 V617F mutant (JAK2V617F) pseudokinase (JH2) domain (JAK2) · developed by Prelude Therapeutics

Phase 1 Most advanced trial
PRLD Developer
1 Registered trials

What is PRT12396?

PRT12396 is an orally bioavailable inhibitor that allosterically binds the pseudokinase (JH2) domain of the mutant JAK2V617F protein, reducing its activation and downstream JAK-STAT signaling while sparing wild-type JAK2. It is being studied in myeloproliferative neoplasms, including polycythemia vera and myelofibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Janus-associated kinase 2 V617F mutant (JAK2V617F) pseudokinase (JH2) domain (JAK2)
Mechanism
Inhibitor of Janus-associated kinase 2 V617F mutant (JAK2V617F) pseudokinase (JH2) domain (JAK2)
Pathways
JAK-STAT signaling, apoptosis
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07469891 Phase 1 Polycythemia Vera (PV) Recruiting PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Polycythemia Vera (PV)Post-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPrimary Myelofibrosis (PMF)

Other drugs acting on JAK2

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT12396

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.